FI963805A - Hermotukisoluista peräisin olevaa neurotrofista tekijää (GDNF) koodaavat yhdistelmä-DNA-tekniset adenovirukset - Google Patents

Hermotukisoluista peräisin olevaa neurotrofista tekijää (GDNF) koodaavat yhdistelmä-DNA-tekniset adenovirukset Download PDF

Info

Publication number
FI963805A
FI963805A FI963805A FI963805A FI963805A FI 963805 A FI963805 A FI 963805A FI 963805 A FI963805 A FI 963805A FI 963805 A FI963805 A FI 963805A FI 963805 A FI963805 A FI 963805A
Authority
FI
Finland
Prior art keywords
gdnf
recombinant adenoviruses
adenovirus
cell
dna sequence
Prior art date
Application number
FI963805A
Other languages
English (en)
Swedish (sv)
Other versions
FI963805A0 (fi
Inventor
Philippe Horellou
Jacques Mallet
Michel Perricaudet
Frederic Revah
Emmanuelle Vigne
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI963805A0 publication Critical patent/FI963805A0/fi
Publication of FI963805A publication Critical patent/FI963805A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI963805A 1994-03-25 1996-09-24 Hermotukisoluista peräisin olevaa neurotrofista tekijää (GDNF) koodaavat yhdistelmä-DNA-tekniset adenovirukset FI963805A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9403542A FR2717824B1 (fr) 1994-03-25 1994-03-25 Virus recombinants, préparation et utilisation en thérapie génique.
PCT/FR1995/000356 WO1995026408A1 (fr) 1994-03-25 1995-03-23 Adenovirus recombinants codant pour le facteur neurotrophique des cellules gliales (gdnf)

Publications (2)

Publication Number Publication Date
FI963805A0 FI963805A0 (fi) 1996-09-24
FI963805A true FI963805A (fi) 1996-09-24

Family

ID=9461438

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963805A FI963805A (fi) 1994-03-25 1996-09-24 Hermotukisoluista peräisin olevaa neurotrofista tekijää (GDNF) koodaavat yhdistelmä-DNA-tekniset adenovirukset

Country Status (14)

Country Link
US (1) US6245330B1 (fi)
EP (1) EP0752004B1 (fi)
JP (1) JPH09510620A (fi)
KR (1) KR100403707B1 (fi)
AT (1) ATE335832T1 (fi)
AU (1) AU704910B2 (fi)
CA (1) CA2184841C (fi)
DE (1) DE69535155T2 (fi)
FI (1) FI963805A (fi)
FR (1) FR2717824B1 (fi)
IL (1) IL113109A0 (fi)
MX (1) MX9604024A (fi)
WO (1) WO1995026408A1 (fi)
ZA (1) ZA952433B (fi)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334238D1 (de) * 1992-09-25 2008-09-25 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
US20020031493A1 (en) * 1994-03-25 2002-03-14 Rhone-Poulenc Rorer S.A. Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
FR2753379B1 (fr) * 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
WO1998046737A2 (en) * 1997-04-15 1998-10-22 University Of Medicine And Dentistry Of New Jersey cDNA FOR HUMAN GDNF AND PROMOTER THEREFOR WHICH ALLOWS REGULATED AND CONSTITUTIVE EXPRESSION
US6043221A (en) 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
IL146694A (en) 2001-11-22 2010-12-30 Biomas Ltd Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament
NZ533833A (en) 2001-12-21 2008-01-31 Salk Inst For Biological Studi Targeted retrograde gene delivery to motor neurons
CA2550459C (en) * 2003-12-18 2009-12-15 Biomas, Ltd. Tellurium derivatives for prevention and treatment of neurodegenerative processes
ES2618787T5 (es) 2006-04-25 2022-10-21 Univ California Administración de factores de crecimiento para el tratamiento de trastornos del SNC
WO2007127839A2 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
CA2690815A1 (en) 2007-06-12 2008-12-18 Case Western Reserve University Targeted cell death
EP2315833B8 (en) 2008-05-20 2015-05-27 Eos Neuroscience, Inc. Vectors for delivery of light-sensitive proteins and methods of use
US20140259192A1 (en) 2011-07-12 2014-09-11 Sanofi Transgenic animal comprising a deletion or functional deletion of the 3'utr of an endogenous gene
US10376562B2 (en) 2013-03-15 2019-08-13 The Jackson Laboratory Methods for promoting wound healing and hair growth comprising GDNF administration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
DE69334238D1 (de) * 1992-09-25 2008-09-25 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
FR2702152B1 (fr) * 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.

Also Published As

Publication number Publication date
FI963805A0 (fi) 1996-09-24
DE69535155T2 (de) 2007-06-28
EP0752004A1 (fr) 1997-01-08
DE69535155D1 (de) 2006-09-21
JPH09510620A (ja) 1997-10-28
CA2184841C (fr) 2009-08-18
ATE335832T1 (de) 2006-09-15
FR2717824A1 (fr) 1995-09-29
IL113109A0 (en) 1995-06-29
AU704910B2 (en) 1999-05-06
ZA952433B (en) 1996-01-15
CA2184841A1 (fr) 1995-10-05
EP0752004B1 (fr) 2006-08-09
KR970702373A (ko) 1997-05-13
KR100403707B1 (ko) 2004-02-11
WO1995026408A1 (fr) 1995-10-05
FR2717824B1 (fr) 1996-04-26
MX9604024A (es) 1997-09-30
US6245330B1 (en) 2001-06-12
AU2141195A (en) 1995-10-17

Similar Documents

Publication Publication Date Title
FI963805A (fi) Hermotukisoluista peräisin olevaa neurotrofista tekijää (GDNF) koodaavat yhdistelmä-DNA-tekniset adenovirukset
Wang et al. Tendon healing in vitro: genetic modification of tenocytes with exogenous PDGF gene and promotion of collagen gene expression
Barkats et al. Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases
Leslie et al. Nerve growth factor contributes to the up-regulation of growth-associated protein 43 and preprotachykinin A messenger RNAs in primary sensory neurons following peripheral inflammation
Cantini et al. Macrophages regulate proliferation and differentiation of satellite cells
Akimoto et al. Adenovirally expressed basic fibroblast growth factor rescues photoreceptor cells in RCS rats.
Ebendal Function and evolution in the NGF family and its receptors
AU667996B2 (en) Modified ciliary neurotrophic factors
Ono et al. Brain-derived neurotrophic factor reduces blood glucose level in obese diabetic mice but not in normal mice
Ebendal NGF in CNS: experimental data and clinical implications
Haase et al. Adenovirus-mediated transfer of the neurotrophin-3 gene into skeletal muscle of pmn mice: therapeutic effects and mechanisms of action
Davies Paracrine and autocrine actions of neurotrophic factors
CA2243261A1 (en) Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions
WO1997026337B1 (en) Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions
EP1674108A3 (en) Osteoporosis treatment
Blottner et al. Neurotrophy and regeneration in vivo
Houlgatte et al. Levels of nerve growth factor secreted by rat primary fibroblasts and iris transplants are influenced by serum and glucocorticoids
Horellou et al. Adenovirus-mediated gene transfer to the central nervous system for Parkinson's disease
Robert et al. Adenovirus-mediated transfer of a functional GAD gene into nerve cells: potential for the treatment of neurological diseases
Lindsay et al. The neurotrophin family of NGF-related neurotrophic factors
CN1155706C (zh) 肌萎缩性侧索硬化的治疗方法
Noel et al. The stimulation of fibroblasts collagen synthesis by neoplastic cells is modulated by the extracellular matrix
DiStefano et al. Regulation of Schwann cell surface and truncated nerve growth factor receptors in vitro by axonal components
Asselot et al. Heparin fragments regulate collagen phenotype and fibronectin synthesis in the skin of genetically diabetic mice
KR970701785A (ko) 글루타메이트 디카르복실라제(gad) 활성을 암호화하는 재조합 바이러스(recombinant viruses coding for a glutamate decarboxylase(gad) activity)

Legal Events

Date Code Title Description
MA Patent expired